.avif){kind=spacer}
Health and Social Care Secretary Wes Streeting, Leeds North West MP Katie White and Medicines & Healthcare products Regulatory Agency (MHRA) Chief Executive Lawrence Tallon paid a joint visit to MNS’ Nexus laboratory this week, offering ringing endorsements of the firm’s Miracus™ technology and of Leeds’ growing status as a national health-tech powerhouse.
Mr Streeting described the painless, self-applied patch as “world-leading, game-changing technology” after watching it deliver a dose in seconds. (yorkshirepost.co.uk) Launching the MHRA’s new digital innovation hub in the city the same day, he added: “There is a global tech revolution in healthcare unfolding, and Yorkshire will help our country lead it.”(gov.uk)
Local support was equally emphatic. “Meeting these brilliant Leeds scientists was truly inspiring… They have turned a bold idea into ground-breaking vaccine technology, showing exactly why Leeds is the UK capital for health-tech innovation,” said MP Katie White, who accompanied the Secretary of State on the tour. (yorkshirepost.co.uk)
Regulatory backing is now on the doorstep. Explaining why the MHRA chose Leeds for its first major base outside the South-East, Mr Tallon said: “We want regulation of health technologies to move at the pace of innovation.” (gov.uk)
Proximity to innovators like MNS, he added, will help ensure “the next generation of health technologies” reaches patients faster.
Independent modelling suggests national roll-out could save the NHS hundreds of millions of pounds—if not billions—by eliminating cold-chain costs, tightening biosecurity through stockpiling, and delivering mass immunisation in days. Beyond pandemic response, the platform promises to slash sharps waste, free clinical staff for frontline care and extend vaccine access to remote or needle-averse communities worldwide.
With endorsement from the UK’s top health decision-maker, cross-party regional champions and the regulator tasked with bringing novel devices safely to market, MNS is poised to convert its lab-bench innovation into a scalable manufacturing programme in WestYorkshire. The company’s next milestones include a first-in-human clinical trial with Leeds Teaching Hospitals and expansion of its automated production line—clear steps toward making needle-free vaccination a reality for everyone.
Media Round Up: